Answer
Cometriq (cabozantinib) treats progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma in adults; if RET mutation status is unknown or negative, potentially lower benefit should be considered before deciding on treatment.
Sources for this answer
- COMETRIQ 20 & 80 mg hard capsulesIpsen Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 15Document updated
Sources checked